NCT04802876 - Efficacy of Tislelizumab and Spartalizumab Across Multiple Cancer-types in Patients with PD1-high MRNA Expressing Tumors | Biotech Hunter

Enrollment

184

Participants

Timeline

Start Date

April 12, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

March 31, 2027

Conditions

MSI-H Colorectal CancerMelanomaAnal CarcinomaMesotheliomaTriple Negative Breast CancerLung AdenocarcinomaCholangiocarcinomaCervical CarcinomaKidney Clear Cell CarcinomaStomach AdenocarcinomaEsophageal AdenocarcinomaUterine AdenocarcinomaHead and Neck Squamous Cell CarcinomaSarcomaLung Squamous Cell CarcinomaUrothelial CarcinomaThyroid CarcinomaHepatocellular CarcinomaUveal MelanomaHER2-positive Breast CancerPancreatic AdenocarcinomaSquamous Esophageal CarcinomaEpithelial Ovarian CancerUterine CarcinosarcomaSmall Cell Lung CancerHormone Receptor Positive / HER2-negative Breast CancerLung Adenocarcinoma EGFR-mutated/ ALK TraslocationColorectal AdenocarcinomaProstate AdenocarcinomaCarcinoma of Unknown PrimaryOther Histology

Interventions

DRUG

Spartalizumab

Spartalizumab (PDR001) 400mg will be given intravenously every 28 days

DRUG

Tislelizumab

Tislelizumab 300mg will be given intravenously every 28 days

Trial Locations (1)

Unknown

Grupo SOLTI, Barcelona